Camtek: The Premium Is Real, And So Is The Runway; Buy

Camtek (CAMT) derives ~70% of revenue from AI-related semiconductor packaging demand and trades at ~41x forward P/E, but the article maintains a Buy rating. The bullish case cites booked HBM orders and a visible earnings reacceleration into 2027, alongside management guidance for >25% revenue growth in 2H 2026 and consensus expectations of ~30% EPS growth in 2027. Near-term growth deceleration is attributed to “industry digestion,” implying the premium valuation is supported by order visibility and accelerating earnings thereafter.

Analysis

CAMT is best viewed as a levered way to own the AI packaging bottleneck rather than a generic semiconductor capex name. The upside mechanism is that inspection/metrology content rises with process complexity, so every incremental layer of HBM/advanced packaging can create more tool demand than the headline unit growth suggests; that favors CAMT and, secondarily, other packaging-adjacent names like ONTO, while leaving more wafer-fab-centric equipment vendors with less direct AI torque.

The main risk is timing, not thesis. At ~41x forward earnings, the stock can de-rate quickly if customer digestion lasts another few quarters or if order bookings prove too front-loaded versus revenue conversion; a one-quarter slip in HBM/packaging ramps can matter more to the multiple than to the long-term story. Watch the next two reporting cycles for backlog conversion and whether management can sustain a 2026 second-half acceleration without leaning on non-recurring order commentary.

Contrarianly, the market may be underestimating how sticky qualification-driven demand can be in advanced packaging: once a tool is embedded in a customer flow, replacement cycles can extend well beyond the initial AI buildout. The flip side is that this makes the name expensive on a peak-sentiment basis; if 2027 EPS growth comes in below the implied ~30% path, the premium is vulnerable even if revenue still grows. The clearest falsifier is a failure to reaccelerate by late 2026, or any sign that HBM/CoWoS capex gets pushed out again.

Key Decisions for Investors

• Buy CAMT only on pullbacks of 10-15% or after an earnings-driven reset; the setup is better as a staged entry than a chase at 41x forward P/E.
• Use a CAMT call spread into the next two earnings prints if you want defined-risk exposure to backlog conversion; upside depends on evidence that orders are turning into revenue, not just on bookings commentary.
• Pair trade: long CAMT / short a basket of slower-growth semiconductor equipment names (AMAT, LRCX) if you want to isolate advanced-packaging beta; CAMT should outperform if packaging intensity keeps rising while broad wafer-fab capex stays muted.
• Set a hard watch item for the next 2 reporting quarters: if second-half 2026 growth fails to inflect or 2027 EPS growth guidance slips materially below ~25-30%, reduce or exit the position.
• If you want a lower-risk expression, own CAMT via a small starter position and add only after management proves order-to-revenue conversion; the stock can stay expensive, but only if the cycle doesn’t slip.